Rasagiline is primarily used in the treatment of Parkinson’s disease. It helps to improve motor function by inhibiting the breakdown of dopamine in the brain, thereby increasing dopamine levels and enhancing nerve signaling involved in movement control. It is often used as an initial monotherapy in early-stage Parkinson’s or as an adjunct to levodopa in more advanced cases to reduce symptom fluctuations. Rasagiline has also been studied for its potential neuroprotective effects, which may help slow disease progression, although this remains an area of ongoing research. Its once-daily dosing regimen improves patient compliance and provides consistent symptom control throughout the day.